Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2012

View Archived Issues

Promising data presented from phase II Cinryze combination trial

GeoVax obtains FDA approval to advance adjuvanted HIV vaccine to clinic

Studies address suitability of allopregnanolone to treat Niemann-Pick disease type C

GM-CSF-adjuvanted vaccine provides long-term protection in HIV model

Hadasit Bio-Holdings to receive further funding from Israeli government

FDA approves first cell-based product made from allogeneic human cells and bovine collagen

Immunogenicity and favorable tolerability reported for H5N1 flu vaccine

New data reported on biOasis immunoconjugate for HER2+ breast cancer

Epistem and GlaxoSmithKline enter biomarker collaboration

Enrollment begins in phase I RX-3117 trial

Calcium channel blocker for hypertension clear to enter clinical testing in China

PX'Therapeutics begins phase I trial of HIV vaccine

Calzada subsidiary discloses encouraging in vitro data on AOD-9603

Hybrigenics clear to conduct phase II inecalcitol study in CLL

Hutchison MediPharma reports new JAK inhibitors

Merck KGaA announces new inhibitors of FADK 1

Isotechnika and FDA reach SPA agreement on voclosporin trial

Novel caspase inhibitors discovered at Banyan Biomarkers

Phase I study of CBLB-502 advances

Novel apoptosis inducers prepared by U.S. university scientists

New Trevena G protein-biased mu opioid receptor ligand has analgesic activity

New RSV vaccines developed at GenVec

Phase III OMS-302 study meets endpoints

FDA accepts CRTX-080 NDA for filing

Attogen patents novel FGFR2IIIc-specific antibodies

Abbott identifies new potential analgesics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...